Sugi Predict

Sugi Predict / Compounds / SCHEMBL6774084

SCHEMBL6774084

SCHEMBL6774084

Cc1nnc(-c2ccc3ncnc(Nc4ccc5c(cnn5Cc5cccc(F)c5)c4)c3c2)o1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ERBB2 P04626 18/20 0.58
▸ EGFR P00533 13/20 0.58
▸ MEN1 O00255 1/20 0.55
▸ RGS12 O14924 1/20 0.55
▸ GMNN O75496 1/20 0.55
▸ ALDH1A1 P00352 1/20 0.55
▸ LMNA P02545 1/20 0.55
▸ RAF1 P04049 1/20 0.55
▸ TP53 P04637 1/20 0.55
▸ CYP1A2 P05177 1/20 0.55
▸ CYP3A4 P08684 1/20 0.55
▸ CYP2D6 P10635 1/20 0.55
▸ MAPT P10636 1/20 0.55
▸ CYP2C9 P11712 1/20 0.55
▸ HPGD P15428 1/20 0.55
▸ ALOX15 P16050 1/20 0.55
▸ NFKB1 P19838 1/20 0.55
▸ APEX1 P27695 1/20 0.55
▸ MAPK1 P28482 1/20 0.55
▸ CYP2C19 P33261 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6768801 0.99 ERBB2 (0.57) ERBB2EGFRMEN1RGS12GMNN
SCHEMBL6767992 0.93 ERBB2 (0.53) ERBB2EGFRMEN1RGS12GMNN
Hydrochloric Acid SCHEMBL6767154 0.92 ERBB2 (0.52) ERBB2EGFRMEN1RGS12GMNN
SCHEMBL6884452 0.91 ERBB2 (0.65) ERBB2EGFRMEN1RGS12GMNN
Hydrochloric Acid SCHEMBL6767364 0.91 ERBB2 (0.64) ERBB2EGFRMEN1RGS12GMNN
SCHEMBL6767913 0.90 ERBB2 (0.56) ERBB2EGFRMEN1RGS12GMNN
Hydrochloric Acid SCHEMBL6767733 0.89 ERBB2 (0.56) ERBB2EGFRMEN1RGS12GMNN
SCHEMBL6763982 0.89 ERBB2 (0.55) ERBB2EGFRMEN1RGS12GMNN
SCHEMBL6767827 0.87 ERBB2 (0.50) ERBB2EGFRMEN1RGS12GMNN
SCHEMBL6764166 0.87 ERBB2 (0.53) ERBB2EGFRMEN1RGS12GMNN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6391874-B1 ANTICARCINOGENIC AGENTS; SKIN DISORDERS SMITHKLINE BEECHAM CORPORATION 2002-05-21 — — US claimed
EP-0912559-A1 FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 1999-05-06 — — EP claimed
WO-1998002434-A1 FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 1998-01-22 — — WO claimed
US-6828320-B2 Enzyme inhibitors; anticancer agents SMITHKLINE BEECHAM CORPORATION 2004-12-07 — — US disclosed
US-20020147214-A1 Heterocyclic compounds NOVARTIS AG (CH) 2002-10-10 — — US disclosed
US-6391874-B1 ANTICARCINOGENIC AGENTS; SKIN DISORDERS SMITHKLINE BEECHAM CORPORATION 2002-05-21 — — US disclosed
EP-0912559-A1 FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 1999-05-06 — — EP disclosed
WO-1998002434-A1 FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 1998-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147214-A1 Heterocyclic compounds BRAF, ABL1, CSK ERBB2 35/4885EGFR 354/4885MEN1 2117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.